Shuttle Pharmaceuticals announces publication of manuscript on SP-1-303

Shuttle Pharmaceuticals announced the publication of a manuscript reporting on the ability of one of the Company’s HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein, ATM, activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells. The published manuscript, titled “Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth,” reports the work of Dr. Mira Jung, Professor of Radiation Medicine at Georgetown University Medical Center, and Dr. Scott Grindrod, Shuttle Pharma’s Principal Scientist, and was published in PLOS ONE, a peer-reviewed open access journal published by the Public Library of Science. SP-1-303, initially discovered and synthesized in Shuttle Pharma’s laboratories by Dr. Grindrod, is one of the Company’s pre-clinical selective Class I HDAC inhibitors.